Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

Refractory Follicular Lymphoma Clinical Trial

— REFRACT  

Official title:

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy (REFRACT): A Randomised Phase II Trial of Investigator Choice Standard Therapy Versus Sequential Novel Therapy Experimental Arms

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05848765
• Other study ID #: RG_22-020
• Status: Recruiting
• Phase: Phase 2
• Start date: September 4, 2023
• Est. completion date: November 30, 2031

Study information

• Verified date: November 2023
• Source: University of Birmingham
• Contact: Trial Coordinator
• Phone: 0121 371 7861
• Email: refract[@]trials.bham.ac.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of the REFRACT clinical trial is to find new therapies with improved outcomes compared to the current standard treatment available, in patients with relapsed or refractory follicular lymphoma. This will be done by comparing patients who have received a new treatment against patients who receive standard treatment based on their response to the treatment received.

Description:

In the REFRACT trial patients with relapsed or refractory follicular lymphoma (rrFL) will be randomised (randomly allocated) to receive a new treatment (experimental treatment) or standard treatment which will be chosen by their doctor prior to entering the trial (called investigator choice standard therapy (ICT)). There are 3 treatment rounds which will happen one after another, testing 3 different experimental treatments. The experimental treatment in each round will be compared to ICT. ICT will be a choice of 1 of 5 standard treatment options including RCHOP, RCVP, lenalidomide and rituximab, bendamustine and rituximab or obinutuzumab and bendamustine. Patients in Round 1 (R1) will be randomised using a 1:1 allocation ratio (meaning patients have a 50/50 chance of receiving the experimental treatment). In Round 1 the experimental treatment is epcoritamab combined with lenalidomide. Patients randomised to epcoritamab and lenalidomide will receive up to 12 28-day cycles of therapy; epcoritamab will be delivered as a subcutaneous injection weekly for cycles 1 and 2 and on day 1 of cycles 3-12. Lenalidomide will be taken orally on days 1-21 of each cycle. Patients in Rounds 2 (R2) and 3 (R3) (experimental treatments yet to be determined) will be randomised using a 1:4 allocation ratio in favour of the experimental treatment (meaning patients are more likely to receive the experimental treatment). The study will recruit 284 patients with rrFL over 5 years. The aim is to identify new therapies which have better outcomes compared to ICT based on patients response to treatment (tested by PET scan) after 24 weeks of therapy. Following treatment patients will be followed up yearly until the end of the trial (up to 10 years).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 284
• Est. completion date: November 30, 2031
• Est. primary completion date: May 31, 2029
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Biopsy proven relapsed or refractory CD20 positive, grade 1-3a follicular lymphoma (biopsy within 3 months of trial entry)

2. Aged 18 years or over

3. Advanced disease that in the opinion of the treating physician requires treatment

4. Patient suitable for standard available therapy at the Investigator's discretion

5. Prior therapy with at least one line of immunochemotherapy. Previous radiotherapy at any time is permitted and will not count as a line of therapy. Previous rituximab monotherapy is also permitted as long as patients have at any time also received at least one line of immunochemotherapy

6. Assessable disease by PET-CT (at least one involved node with long diameter >1.5cm, or extranodal lesion >1cm )

7. ECOG performance status of 0, 1 or 2 at trial entry

8. Adequate organ function defined as; i. ANC = 1.0 x 109/L (growth factor use is permitted) ii. Platelet count = 75 x 109/L, or = 50 x 109/L if bone marrow infiltration or splenomegaly iii. ALT and AST level =3 x ULN iv. Direct bilirubin level = 2 x ULN, unless due to Gilbert's syndrome v. CrCl = 50mL/min (by Cockcroft-Gault formula) vi. PT, INR and aPTT = 1.5 x ULN, unless receiving anticoagulation vii. LVEF within normal limits by MUGA or echocardiography

9. Able to provide written informed consent

10. Women of childbearing potential (or their partners) must use an effective form of contraception

Exclusion Criteria:

1. Current (or within 1 year) transformation to high grade lymphoma, including grade 3b follicular lymphoma (patients with historical high-grade transformation over 1 year ago are eligible)

2. Non-Fluorodeoxyglucose (FDG) avid disease

3. Prior allogenic stem cell transplantation (SCT) or solid organ transplant

4. Prior treatment with lenalidomide

5. Treatment with CAR-T therapy within 100 days of starting trial treatment

6. SCT or maintenance therapy planned within 24 weeks of starting treatment (patients planning SCT/maintenance after at least 24 weeks of treatment are eligible)

7. Immunochemotherapy with a platinum-containing regimen planned

8. Known serological positivity for HIV or uncontrolled HCV

9. Hepatitis B surface antigen (HBsAg) positive and/or detectable viral DNA. Patients positive for Hepatitis B core antibody (anti-HBc) but viral DNA negative are eligible

10. Other malignancy within 2 years of enrolment, excepting cervical carcinoma stage 1B or less, non-invasive basal cell or squamous cell skin carcinoma, non-invasive, superficial bladder cancer, prostate cancer with a current PSA level <0.1ng/mL, any curable cancer with a CR of > 2 years duration

11. Active systemic infection requiring treatment

12. Current or prior CNS involvement with lymphoma

13. History of allergy or anaphylaxis to anti-CD20 monoclonal antibody therapy

14. Known hypersensitivity to any of the experimental arm IMPs. Patients with a known hypersensitivity to a control arm regimen may still be eligible if they have no hypersensitivity to other potential control arm IMPs.

15. Serious medical or psychiatric illness likely to interfere with participation in this clinical study

16. Recent cancer treatment (chemotherapy, immunotherapy, biological therapy) within 4 weeks of starting trial treatment; systemic steroid treatment (prednisolone > 10mg daily (or equivalent)) within 7 days of cycle 1 day 1 dosing

17. Unwilling to use appropriate contraception methods whilst on study treatment and for 12 months following end of treatment (or 18 months for female patients whose ICT regimen contains obinutuzumab)

18. Women who are pregnant or breastfeeding

19. Prior treatment with the experimental therapy under investigation

20. Major surgery within 30 days of starting treatment

21. Severe arrhythmias, heart failure, previous myocardial infarction, acute inflammatory heart disease for ICT regimen containing doxorubicin, or severe heart failure (New York Heart Association Class IV) or severe, uncontrolled cardiac disease for ICT regimen containing rituximab

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, Follicular
• Refractory Follicular Lymphoma
• Relapsed Follicular Lymphoma

Intervention

Drug:
• Epcoritamab
Bispecific antibody
• Lenalidomide
Immunomodulatory agent
• Rituximab
Monoclonal antibody
• Obinutuzumab
Monoclonal antibody
• Bendamustine
Alkylating agent (chemotherapy drug)
• Vincristine
Antineoplastic, Vinca Alkaloid
• Doxorubicin
Anthracycline
• Cyclophosphamide
Alkylating agent (chemotherapy drug)
• Prednisone
Corticosteroid
• Investigation agent 2
The drug used in round 2 is yet to be confirmed, round 2 is estimated to open in Q4 2025 and the record will be updated when the drug has been confirmed
• Investigation agent 3
The drug used in round 3 is yet to be confirmed, round 3 is estimated to open in Q3 2027 and the record will be updated when the drug has been confirmed

Locations

Country	Name	City	State
United Kingdom	NHS Grampian	Aberdeen
United Kingdom	Belfast Health & Social Care Trust	Belfast
United Kingdom	University Hospitals Birmingham NHS Foundation Trust	Birmingham
United Kingdom	Blackpool Teaching Hospitals NHS Foundation Trust	Blackpool
United Kingdom	Cambridge University Hospitals NHS Foundation Trust	Cambridge
United Kingdom	Cardiff and vale University LHB	Cardiff
United Kingdom	University Hospitals Coventry and Warwickshire NHS Trust	Coventry
United Kingdom	Croydon Health Services NHS Trust	Croydon
United Kingdom	NHS Greater Glasgow and Clyde	Glasgow
United Kingdom	The Leeds Teaching Hospitals NHS Trust	Leeds
United Kingdom	The Clatterbridge Cancer Centre NHS Foundation Trust	Liverpool
United Kingdom	Guy's and St Thomas' NHS Foundation Trust	London
United Kingdom	King's College Hospital NHS Foundation Trust	London
United Kingdom	The Royal Marsden NHS Foundation Trust	London
United Kingdom	University College London Hospital NHS Foundation Trust	London
United Kingdom	The Christie NHS Foundation Trust	Manchester
United Kingdom	The Newcastle Upon Tyne Hospitals NHS Foundation Trust	Newcastle
United Kingdom	Norfolk and Norwich University Hospitals NHS Foundation Trust	Norwich
United Kingdom	Nottingham University Hospitals NHS Trust	Nottingham
United Kingdom	Oxford University Hospitals NHS Foundation Trust	Oxford
United Kingdom	Sheffield Teaching Hospitals NHS Foundation Trust	Sheffield
United Kingdom	University Hospital Southampton NHS Foundation Trust	Southampton
United Kingdom	University Hospital of North Midlands NHS Trust	Stoke-on-Trent
United Kingdom	Swansea Bay University Local Health Board	Swansea
United Kingdom	Torbay and South Devon NHS Foundation Trust	Torquay

Sponsors (3)

Lead Sponsor	Collaborator
University of Birmingham	Cancer Research UK, Genmab

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete metabolic response (CMR)	CMR will be assessed by PET-CT using the Deauville 5-point scale and Lugano 2014 criteria. Patients who die from any cause or relapse/progress prior to this time-point will be considered non-responders. Patients who don't have a PET-CT scan within the protocol defined window or withdraw from the trial prior to this time-point will be considered non outcome evaluable. Patients who undergo stem-cell transplant (SCT) within 24 weeks of randomisation, patients who fail to start treatment and patients whose ineligibility is deemed to impact upon response to treatment will be replaced and hence not included in the analysis of this outcome	24 weeks
Secondary	Overall metabolic response	Complete metabolic response (CMR) and partial metabolic response (PMR) will be assessed by PET-CT. Patients who die from any cause or relapse/progress prior to this time-point will be considered non-responders. Patients who undergo stem-cell transplant (SCT) within 24 weeks of randomisation, patients who fail to start treatment and patients whose ineligibility is deemed to impact upon response to treatment will be replaced and hence not included in the analysis of this outcome	24 weeks
Secondary	Progression free survival (PFS)	The time from randomisation to the date of first disease progression or death. Patients who are alive and relapse/progression at the time of analysis will be censored at their date last seen	10 years
Secondary	Overall survival (OS)	The time from randomisation to the date of death from any cause. Patients who are alive at the time of analysis will be censored at their date last seen	10 years
Secondary	Duration of response (DoR)	The time from complete and partial metabolic response by PET-CT to relapse/progression or death from any cause. Patients who are alive and relapse/progression free at the time of analysis will be censored at their date last seen	10 years
Secondary	Duration of complete response (DoCR)	The time from complete metabolic response by PET-CT to relapse/progression or death from any cause. Patients who are alive and relapse/progression free at the time of analysis will be censored at their date last seen	10 years
Secondary	Time to next treatment (TTNT)	The time from randomisation to the start date of next treatment for lymphoma. Patients who are responding (CMR or PMR) who receive consolidation radiotherapy will not be considered an event and will be censored at their date last seen if no other treatment for lymphoma is reported. Patients who die without having started next lymphoma treatment will be considered a competing risk at their date of death, and patients who are alive and have not started next lymphoma treatment at the time of analysis will be censored at their date last seen	10 years
Secondary	Adverse events (AEs)	Collected and reported in accordance with CTCAE version 5 defined as the number of patients who experience one or more grade 3 or 4 adverse events or serious adverse events of any grade	Collected from start of treatment until 60 days after treatment
Secondary	Quality of Life (QoL)	Measured using the EQ-5D-5L and FACT-Lym	Collected pre-treatment, day 1 of cycle 3 (28 day cycles), 24 weeks from treatment start and then every 24 weeks in non-progressed patients until the end of the study (10 years)
Secondary	Quality of Life (QoL)	Measured using the FACT-Lym	Collected pre-treatment, day 1 of cycle 3 (28 day cycles), 24 weeks from treatment start and then every 24 weeks in non-progressed patients until the end of the study (10 years)